Effect of hydroxychloroquine, azithromycin and lopinavir/ritonavir on the QT corrected interval in patients with COVID-19

Autor: Clea González-Maniega, Elena Tundidor-Sanz, Miguel Rodríguez-Santamarta, Rubén Bergel-García, Paula Menendez-Suarez, Felipe Fernández-Vázquez, Enrique Sánchez-Muñoz, Samuel Del Castillo-García, Silvia Prieto-González, Javier Borrego-Rodriguez, Tomás Benito-González, Julio Echarte-Morales, Carlos Minguito-Carazo
Rok vydání: 2021
Předmět:
Male
Lopinavir/ritonavir
Kaplan-Meier Estimate
Azithromycin
030204 cardiovascular system & hematology
Gastroenterology
Lopinavir
Electrocardiography
0302 clinical medicine
Anti-Infective Agents
DT
Double therapy
Prospective Studies
030212 general & internal medicine
VA
ventricular arrhythmias
COVID-19
Coronavirus disease 2019
Incidence (epidemiology)
Middle Aged
Hypokalemia
cardiovascular system
Drug Therapy
Combination
Female
medicine.symptom
Cardiology and Cardiovascular Medicine
Hydroxychloroquine
circulatory and respiratory physiology
medicine.drug
congenital
hereditary
and neonatal diseases and abnormalities
medicine.medical_specialty
TT
Triple therapy
QT interval
Article
03 medical and health sciences
Internal medicine
medicine
Humans
cardiovascular diseases
Aged
QT corrected interval
QTc
corrected QT interval
Ritonavir
business.industry
COVID-19
HIV Protease Inhibitors
COVID-19 Drug Treatment
SCD
sudden cardiac death
COVID-19
Hydroxychloroquine
business
Zdroj: Journal of Electrocardiology
ISSN: 0022-0736
Popis: Background: Administration of Hydroxychloroquine and Azithromycin in patients with coronavirus disease 2019 (COVID-19) prolongs QTc corrected interval (QTc). The effect and safety of Lopinavir/Ritonavir in combination with these therapies have seldom been studied. Objectives: Our aim was to evaluate changes in QTc in patients receiving double (Hydroxychloroquine + Azithromycin) and triple therapy (Hydroxychloroquine + Azithromycin + Lopinavir/Ritonavir) to treat COVID-19. Secondary outcome was the incidence of in-hospital all-cause mortality. Methods: Patients under treatment with double (DT) and triple therapy (TT) for COVID-19 were consecutively included in this prospective observational study. Serial in-hospital electrocardiograms were performed to measure QTc at baseline and during therapy. Results: 168 patients (±66.2 years old) were included: 32.1% received DT and 67.9% received TT. The mean baseline QTc was 410.33 ms. Patients under DT and TT prolonged QTc interval respect baseline values (p
Highlights • What is known? • Hydroxychloroquine and Azithromycin prolong QTc in patients with COVID-19, prompting ECG monitoring due to increased risk of ventricular arrythmias. • What is the new? • The impact of Lopinavir/Ritonavir in addition to Hydroxychloroquine and Azithromycin on QTc has not been studied previously. In our series, triple therapy did not further prolong QTc interval compared to double therapy.
Databáze: OpenAIRE
Externí odkaz: